INZY
Income statement / Annual
Last year (2023), Inozyme Pharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Inozyme Pharma, Inc.'s net income was -$71.17 M.
See Inozyme Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.29 M |
$1.18 M |
$1.05 M |
$217,000.00 |
$83,000.00 |
$26,000.00 |
| Gross Profit |
-$1.29 M |
-$1.18 M |
-$1.05 M |
-$217,000.00 |
-$83,000.00 |
-$26,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$54.85 M
|
$47.85 M
|
$37.72 M
|
$46.49 M
|
$16.22 M
|
$8.10 M
|
| General & Administrative
Expenses |
$20.80 M
|
$20.83 M
|
$18.93 M
|
$10.55 M
|
$4.59 M
|
$3.49 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$20.80 M
|
$20.83 M
|
$18.93 M
|
$10.55 M
|
$4.59 M
|
$3.49 M
|
| Other Expenses |
$0.00 |
-$319,000.00 |
-$189,000.00 |
$247,000.00 |
-$24,000.00 |
$4.35 M |
| Operating Expenses |
$75.65 M |
$68.68 M |
$56.65 M |
$57.04 M |
$20.81 M |
$11.59 M |
| Cost And Expenses |
$75.65 M |
$68.68 M |
$56.65 M |
$57.04 M |
$20.81 M |
$11.59 M |
| Interest Income |
$7.84 M |
$1.93 M |
$211,000.00 |
$370,000.00 |
$1.11 M |
$284,000.00 |
| Interest Expense |
$3.33 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$833,000.00
|
$1.18 M
|
$1.05 M
|
$217,000.00
|
$83,000.00
|
$26,000.00
|
| EBITDA |
-$74.81 M
|
-$65.88 M
|
-$55.97 M
|
-$56.82 M
|
-$20.72 M
|
-$11.57 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$4.48 M
|
$1.61 M
|
$22,000.00
|
$617,000.00
|
$1.08 M
|
$4.63 M
|
| Income Before Tax |
-$71.17 M |
-$67.06 M |
-$56.62 M |
-$56.42 M |
-$19.72 M |
-$6.96 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.61 M |
-$211,000.00 |
-$587,000.00 |
-$1.11 M |
$4.63 M |
| Net Income |
-$71.17 M |
-$65.45 M |
-$56.41 M |
-$55.84 M |
-$18.62 M |
-$6.96 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.37 |
-1.73 |
-2.39 |
-2.39 |
-1.23 |
-0.46 |
| EPS Diluted |
-1.37 |
-1.73 |
-2.39 |
-2.39 |
-1.23 |
-0.46 |
| Weighted Average Shares
Out |
$51.84 M
|
$37.76 M
|
$23.56 M
|
$23.38 M
|
$15.16 M
|
$15.14 M
|
| Weighted Average Shares
Out Diluted |
$51.84 M
|
$37.76 M
|
$23.56 M
|
$23.38 M
|
$15.16 M
|
$15.14 M
|
| Link |
|
|
|
|
|
|
